Pharmacokinetics of quinine in chronic liver disease.

16Citations
Citations of this article
14Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

The pharmacokinetics of quinine were investigated in a) six healthy male Thai subjects, and b) nine male Thai patients with a moderate degree of chronic liver disease, after a single oral dose of 600 mg quinine sulphate. tmax and t1/2.2 were significantly prolonged in patients (median [range] tmax 2 [1‐5] vs 1.6 [0.8‐2] h; t1/2,z 23.4 [17.4‐41.7] vs 9.7 [7.8‐17.2] h), and Vz/F was significantly larger (median [range] 4.21 [2.33‐15.87] vs 2.78 [1.49‐3.38] 1 kg‐1). Median (range) concentration of the plasma unbound Qn fraction collected from the patients at 4 h after drug administration was 17 (8.4‐17.8)% of total drug concentration. Copyright © 1995, Wiley Blackwell. All rights reserved

Cite

CITATION STYLE

APA

Auprayoon, P., Sukontason, K., Na‐Bangchang, K., Banmairuroi, V., Molunto, P., & Karbwang, J. (1995). Pharmacokinetics of quinine in chronic liver disease. British Journal of Clinical Pharmacology, 40(5), 494–497. https://doi.org/10.1111/j.1365-2125.1995.tb05795.x

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free